Pharmaceutical and bio-tech companies spend vast amounts of time and resource in R&D before a drug finally comes to market. This is also the case for learning and research institutions such as universities. In addition, the global distribution of the drug will add significant further costs in terms of manufacturing, distribution, advertising and marketing.

Pharmaceutical, bio-tech companies and universities are increasingly entering into strategic alliances with other companies in the industry through licensing, co-promotion and co-development / distribution agreements. The basis of the royalty calculations in these agreements are often very complex depending on various factors such as territory of distribution, grant of patents, data exclusivity and existence of other competitive drugs. As a result, any minor error in reporting could lead to a significant under-payment.

We have experience in assisting companies in the pharmaceutical industry maximise and recover their contractual cash-flow through detailed forensic audits which result in improved future terms in the agreements and build stronger relationships between business partners.